ReviewTherapeutic delivery2010
Intracellular delivery of RNA-based therapeutics using aptamers.
Review in Therapeutic delivery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 76 citations in OpenAlex.
- Enhancing the intracellular delivery of antisense oligonucleotides (ASO) : a comparative study of aptamer, vitamin E, and cholesterol ASO conjugates.RSC advances · 2025Article
- Prodrug Strategy for PROTACs: High Efficiency and Low Toxicity.ACS omega · 2025Review
- GPC3-mediated lysosome-targeting chimeras (GLTACs) for targeted degradation of membrane proteins.Acta pharmaceutica Sinica. B · 2025Article
- Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation.ChemMedChem · 2024Review
- Impact of Peptide Sequence on Functional siRNA Delivery and Gene Knockdown with Cyclic Amphipathic Peptide Delivery Agents.Molecular pharmaceutics · 2023Article
- Targeted Protein Degradation: Clinical Advances in the Field of Oncology.International journal of molecular sciences · 2022Review
- Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope.Acta pharmaceutica Sinica. B · 2022Review
- PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).Signal transduction and targeted therapy · 2022Review
- Synthesis and Exon-Skipping Properties of a 3'-Ursodeoxycholic Acid-Conjugated Oligonucleotide TargetingMolecules (Basel, Switzerland) · 2021Article
- Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy.Biomaterials research · 2021Review
- AptaBlocks Online: A Web-Based Toolkit for the In Silico Design of Oligonucleotide Sticky Bridges.Journal of computational biology : a journal of computational molecular cell biology · 2020Article
- An in Vitro Selection Strategy Identifying Naked DNA That Localizes to Cell Nuclei.Journal of the American Chemical Society · 2019Article
- Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells.Molecular therapy. Nucleic acids · 2018Article
- Aptamer Cell-Based Selection: Overview and Advances.Biomedicines · 2017Review
- Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.Scientific reports · 2017Article
- Aptamers as Valuable Molecular Tools in Neurosciences.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017Review
- Targeting Insulin Receptor with a Novel Internalizing Aptamer.Molecular therapy. Nucleic acids · 2016Article
- Aptamers and Their Significant Role in Cancer Therapy and Diagnosis.Biomedicines · 2015Review
- Manipulating the in vivo immune response by targeted gene knockdown.Current opinion in immunology · 2015Review
- Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine.Theranostics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The clinical potential of siRNAs for silencing genes critical to disease progression is clear, but a fail-proof method for delivering siRNAs to the cytoplasm of diseased tissues or cells has yet to be identified. A variety of delivery approaches have been explored to directly or indirectly couple siRNAs to delivery vehicles. This review explores the use of synthetic single-stranded DNA and RNA aptamers as a means to deliver siRNAs, shRNAs and antisense oligonucleotides for therapeutic intervention. Topics covered include: the advantages and challenges of using aptamers as delivery tools; current aptamer-mediated siRNA delivery platforms for the treatment of cancer and HIV; and emerging methodologies for the identification of aptamers capable of internalizing into target cell types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.